Modality
Nanobody
MOA
TROP-2 ADC
Target
SHP2
Pathway
Proteasome
IPF
Development Pipeline
Preclinical
~Mar 2010
→ ~Jun 2011
Phase 1
~Sep 2011
→ ~Dec 2012
Phase 2
~Mar 2013
→ ~Jun 2014
Phase 3
~Sep 2014
→ ~Dec 2015
NDA/BLA
~Mar 2016
→ ~Jun 2017
Approved
Sep 2017
→ Jun 2031
ApprovedCurrent
NCT03941849
1,655 pts·IPF
2021-09→2030-02·Terminated
NCT03402177
1,014 pts·IPF
2017-09→TBD·Not yet recruiting
NCT05489667
121 pts·IPF
2019-03→2031-06·Terminated
2,790 total pts1 indication
CompletedCurrentUpcoming
Catalysts (3)
2026-01-222mo agoPh1 Dose Esc· IPF
2030-02-053.9y awayPh3 Readout· IPF
2031-06-015.2y awayPh3 Readout· IPF
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Approved
Not yet…
Approved
Termina…
Approved
Termina…
Catalysts
Ph1 Dose Esc
2026-01-22 · 2mo ago
IPF
Ph3 Readout
2030-02-05 · 3.9y away
IPF
Ph3 Readout
2031-06-01 · 5.2y away
IPF
TerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03941849 | Approved | IPF | Terminated | 1655 | LiverFat |
| NCT03402177 | Approved | IPF | Not yet recr... | 1014 | PANSS |
| NCT05489667 | Approved | IPF | Terminated | 121 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 |